Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 301–400 of 780
Structural Biology of the Membrane Attack Complex
Sonnen, A. F. ‐., & Henneke, P. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-8881-6_6 · Cited by 31
Zewde, N. T., & Morikis, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198644 · Cited by 33
Lukacs, M., Roberts, T., Chatuverdi, P., & Stottmann, R. W. (2019) · eLife · doi:10.7554/elife.45248 · Cited by 27
“Blockade of complement in these patients via eculizumab, a monoclonal antibody that inhibits the conversion of C5 to C5a and C5b, has been shown to greatly improve survival (Brodsky et al., 2008; Rother et al., 2007; Hillmen et al., 2007; Hillmen et al., 2006).”
BackgroundComplement and Cancer—A Dysfunctional Relationship?
Thurman, J. M., Laskowski, J., & Nemenoff, R. A. (2020) · Antibodies · doi:10.3390/antib9040061 · Cited by 29
The allosteric modulation of complement C5 by knob domain peptides
Macpherson, A., Laabei, M., Ahdash, Z., Graewert, M. A., Birtley, J. R., Schulze, M. E. D., Crennell, S. J., Robinson, S. A., Holmes, B., Oleinikovas, V., et al. (2021) · eLife · doi:10.7554/elife.63586 · Cited by 28
Singh, P., Gao, X., Kleijn, H. J., Bellanti, F., & Pelto, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.696387 · Cited by 29
“It does not interact with earlier (proximal) components in the complement-activation pathway thus preserving complement functioning at that level, which is required for opsonization and immune complex clearance (29, 30).”
BackgroundAn update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits
Li, M., & Xu, G. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab269 · Cited by 26
“This situation is due to the structural characteristics of eculizumab; it is a recombinant intact immunoglobulin of human and murine origin in which CH2 and CH3 constant regions from IgG4 are fused to the IgG2 hinge region and CH1 domain, and then paired with a Kappa LC [35].”
BackgroundA novel CRIg‐targeted complement inhibitor protects cells from complement damage
Qiao, Q., Teng, X., Wang, N., Lu, R., Guo, L., Zhang, X., Du, Y., Wang, W., Chen, S., Wu, Q., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-258046 · Cited by 26
“34), there were few successes until the development of eculizumab, an antibody against C5 by Alexion Pharmaceutics (Cheshire, CT, USA) in 2007 (35, 36).”
BackgroundMonoclonal Antibodies Based on Hybridoma Technology
Yagami, H., Kato, H., Tsumoto, K., & Tomita, M. (2013) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.13.2 · Cited by 34
Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations
Lapeyraque, A., Wagner, É., Phan, V., Clermont, M., Mérouani, A., Frémeaux‐Bacchi, V., Goodship, T. H. J., & Robitaille, P. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0803-4 · Cited by 26
“It has just been approved for the treatment of paroxysmal nocturnal hemoglobinuria [22].”
BackgroundA closer look at paroxysmal nocturnal hemoglobinuria
Rachidi, S., Musallam, K. M., & Taher, A. T. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.04.002 · Cited by 25
“The early clinical studies of eculizumab with rheumatoid arthritis and systemic lupus erythematosis provided information about the appropriate dosing regimens [106,107].”
BackgroundMcConnell, A. D., Do, M., Neben, T. Y., Spasojevic, V., MacLaren, J., Chen, A. P., Altobell, L. J., Macomber, J. L., Berkebile, A. D., Horlick, R. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049458 · Cited by 29
Eculizumab in refractory myasthenic crisis
Yeo, C. J. J., & Pleitez, M. Y. (2018) · Muscle & Nerve · doi:10.1002/mus.26124 · Cited by 25
Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria
Merrill, S. A., & Brodsky, R. A. (2018) · Hematology · doi:10.1182/asheducation-2018.1.371 · Cited by 25
Emerging Therapeutic Modalities against COVID-19
Malik, S., Gupta, A., Zhong, X., Rasmussen, T. P., Manautou, J. E., & Bahal, R. (2020) · Pharmaceuticals · doi:10.3390/ph13080188 · Cited by 31
“Eculizumab, approved for the treatment of paroxysmal nocturnal hemoglobinuria, targets the complement protein C5 to regulate inflammatory response [55].”
BackgroundSiddiqi, Z. A., Nowak, R. J., Mozaffar, T., O’Brien, F., Yountz, M., Patti, F., & the REGAIN Study Group (2021) · Muscle & Nerve · doi:10.1002/mus.27422 · Cited by 25
“Eculizumab is a humanized monoclonal antibody that specifically inhibits cleavage of terminal complement protein C5.(25) The 6-month, phase 3, randomized, placebo-controlled REGAIN study and its open-label extension (OLE) evaluated efficacy and safety of eculizumab in refractory AChR gMG.”
BackgroundFeng, X., Song, Z., Wu, M., Liu, Y., Luo, S., Zhao, C., & Zhang, W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.725700 · Cited by 25
“Eculizumab is a-C5 monoclonal antibody, which inhibits C5 cleavage (30) and prevents damage to the neuromuscular junction from complement cascade in MG patients with AChR antibody (31).”
BackgroundComplement‐targeted therapeutics: An emerging field enabled by academic drug discovery
Lamers, C., Ricklin, D., & Lambris, J. D. (2023) · American Journal of Hematology · doi:10.1002/ajh.26875 · Cited by 35
“The clinical introduction of pegcetacoplan therefore marks a second watershed moment for the treatment of PNH after the approval of eculizumab some 15 years ago.(2) The hematological disorder PNH is driven by complement-mediated hemolysis due to acquired mutations that lead to a lack of glycosylphosphatidylinositol-an…”
BackgroundBuried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors
Yang, C., Phillips, J. G., Stuckey, J. A., Bai, L., Sun, H., Delproposto, J., Brown, W. C., & Chinnaswamy, K. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00299 · Cited by 25
Brando, B., Gatti, A., & Preijers, F. W. M. B. (2019) · PubMed Central · Cited by 42
Eculizumab for treatment of asthma
Smith, S. G., Watson, B. M., Clark, G., & Gauvreau, G. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.668517 · Cited by 24
“As such, it behaves only as a blocking antibody that prevents the cleavage and thus activation of C5, with no other downstream activity [55].”
BackgroundParoxysmal nocturnal hemoglobinuria: Where we stand
Panse, J. (2023) · American Journal of Hematology · doi:10.1002/ajh.26832 · Cited by 32
“commercial manufacturing of eculizumab may also permit the evaluation of new formulations of eculizumab in future development programs”.(2) Indeed biweekly infusion intervals the recognition of”
BackgroundTherapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease
Trambas, I. A., Coughlan, M. T., & Tan, S. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108758 · Cited by 28
“The emergence of the anti-C5 monoclonal antibody Eculizumab marked the development of the first complement-targeted drug approved for clinical use [136,137].”
BackgroundThe efficacy and safety of eculizumab in patients and the role of C5 polymorphisms
Bouwman, H. B., & Guchelaar, H. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104134 · Cited by 24
Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria
Dezern, A. E., Uknis, M. E., Yuan, X., Mukhina, G. L., Varela, J. C., Saye, J. A., Pu, J. J., & Brodsky, R. A. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.06.007 · Cited by 24
“The drug decreases intravascular hemolysis, reduces thrombosis risk, and improves quality of life in PNH [6, 7] through inhibiting formation of the MAC [8].”
BackgroundZelek, W. M., Taylor, P. R., & Morgan, B. P. (2019) · Immunology · doi:10.1111/imm.13083 · Cited by 25
Murai, H., Uzawa, A., Suzuki, Y. A., Imai, T., Shiraishi, H., Suzuki, H., Okumura, M., O’Brien, F., Wang, J., Fujita, K. P., et al. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.08.004 · Cited by 24
“Eculizumab is a humanized monoclonal antibody specifically targeted to human terminal complement protein C5 [9].”
Yamaguchi, N., Misawa, S., Sato, Y., Nagashima, K., Katayama, K., Sekiguchi, Y., Iwai, Y., Amino, H., Suichi, T., Yokota, T., et al. (2016) · JMIR Research Protocols · doi:10.2196/resprot.6610 · Cited by 23
“Eculizumab is a humanized monoclonal antibody that specifically binds to complement component 5 (C5) and suppresses its cleavage into active chemotaxis mediator C5a and attacks complex component C5b, thereby inhibiting membrane attack complex (MAC) formation [11,12].”
BackgroundDing, T., & Sun, J. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2747-8 · Cited by 25
“In addition to this, it was found that an increased expression of CFI and C4bp could inhibit the formation of the C3 convertase in the classical pathway, while the expression of CFA and CFP in the HAP-NPs did not show any obvious variation [37,38].”
BackgroundHumoral-Targeted Immunotherapies in Multiple Sclerosis
Lulu, S., & Waubant, E. L. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0164-3 · Cited by 26
Biological Drugs in Guillain-Barré Syndrome: An Update
Motamed-Gorji, N., Matin, N., Tabatabaie, O., Pavone, P., Romano, C., Falsaperla, R., & Vitaliti, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666161213114904 · Cited by 23
“Eculizumab binds to C5 in PNH patients and prevents blood cells from hemolysis [34].”
BackgroundTherapeutic Inhibition of Complement: Well Worth the Risk
Barnum, S. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.009 · Cited by 26
A review of thrombotic microangiopathies in multiple myeloma
Portuguese, A. J., Gleber, C. D., Passero, F. C., & Lipe, B. C. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106195 · Cited by 24
C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh–/– Cfd–/– mice
Zhang, Y., Keenan, A., Dai, D., May, K. S., Anderson, E. E., Lindorfer, M. A., Henrich, J. B., Pitcher, G. R., Taylor, R. P., & Smith, R. J. (2020) · JCI Insight · doi:10.1172/jci.insight.135758 · Cited by 25
“Introduction Therapeutic complement inhibition using eculizumab, a humanized anti-C5 mAb, was introduced for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in 2002 (1, 2).”
BackgroundBhutani, D., Assal, A., Mapara, M. Y., Prinzing, S., & Lentzsch, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.016 · Cited by 23
Inflammation-Driven Plaque Erosion in Atherosclerosis: A Focus on Complement System Pathways
Ramoni, D., Carbone, F., Kraler, S. C., Vece, D. D., Montecucco, F., & Liberale, L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01279-x · Cited by 27
“Eculizumab, a monoclonal antibody that blocks C5 activation, has demonstrated potential in reducing complement-mediated damage in conditions like paroxysmal nocturnal hemoglobinuria (PNH) [52].”
Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease
Shadid, A., Hok, K. D., Domozhirov, A. Y., Mills, T., Doursout, M. F., Banda, N. K., Restrepo, M. I., & Shivshankar, P. (2025) · Immune Network · doi:10.4110/in.2025.25.e32 · Cited by 25
“Initially developed for PNH, eculizumab has demonstrated long-term efficacy in the attenuation of hemolysis, transfusion dependence, and thromboembolic risk (291,292).”
Complement testing in the clinical laboratory
Willrich, M. A. V., Braun, K. M. P., Moyer, A. M., Jeffrey, D. H., & Frazer‐Abel, A. A. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1907297 · Cited by 25
“C5b-9 deposition on these cells can be measured by confocal microscopy, flow cytometry, or cell viability assays [150].”
BackgroundInfluentialRecent developments of neuroprotective agents for degenerative retinal disorders
Wu, J., Ou, K., Li, Y., Liu, L., Li, H., Cox, K. H. M., Liu, J., & Dick, A. D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335140 · Cited by 26
“Eculizumab is a monoclonal antibody that binds to C5 and blocks its proteolytic activation (Rother et al., 2007).”
BackgroundComplement and myasthenia gravis
Sanderson, N. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.08.018 · Cited by 22
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
Martí-Carvajal, A. J., Anand, V., Cardona, A. F., & Solà, I. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010340.pub2 · Cited by 30
Laskowski, J., Renner, B., Quintrec, M. L., Panzer, S. E., Hannan, J. P., Ljubanović, D. G., Ruseva, M. M., Borza, D., Antonioli, A. H., Pickering, M. C., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.036 · Cited by 22
Development of Antibody-Based Therapeutics: Translational Considerations
Tabrizi, M. A., Klakamp, S. L., & Bornstein, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3 · Cited by 26
Li, X., Jusko, W. J., & Cao, Y. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250134 · Cited by 22
Kinoshita, T. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.004 · Cited by 21
Zelek, W. M., Stott, M. I., Walters, D., Harris, C. L., & Morgan, B. P. (2018) · Immunology · doi:10.1111/imm.12982 · Cited by 24
Harder, M. J., Höchsmann, B., Dopler, A., Anliker, M., Weinstock, C., Skerra, A., Simmet, T., Schrezenmeier, H., & Schmidt, C. Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01639 · Cited by 27
Emerging drugs for the treatment of myasthenia gravis
Menon, D., Pincheira, A. U., & Bril, V. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1952982 · Cited by 23
Kojima, T., Inoue, D., Wajima, T., Uchida, T., Yamada, M., Ohsawa, I., & Oda, T. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2068445 · Cited by 22
“Moreover, levels of C5a and C5b-9 showed a significant positive correlation with CIC-mRF levels (p 0.01) (Figure 3).”
BackgroundInfluentialThe role of C5a receptors in autoimmunity
Schanzenbacher, J., Kähler, K. H., Mesler, E. B., Kleingarn, M., Karsten, C. M., & Seiler, D. L. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152413 · Cited by 23
Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
Bravo‐Pérez, C., Guarnera, L., Williams, N. D., & Visconte, V. (2023) · Medicina · doi:10.3390/medicina59091612 · Cited by 34
“With the advent of complement inhibitors in clinical practice, the survival of patients with PNH has become close to that of sex-and age-matched controls [60,61].”
BackgroundAnticorps thérapeutiques et dérivés : une palette de structures pour une pléthore d’indications
Beck, A., Wagner‐Rousset, E., Wurch, T., & Corvaïa, N. (2009) · médecine/sciences · doi:10.1051/medsci/200925121024 · Cited by 28
Consequences of dysregulated complement regulators on red blood cells
Thielen, A. J. F., Zeerleder, S. S., & Wouters, D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.003 · Cited by 23
Guillain–Barré syndrome: update on immunobiology and treatment
Kaida, K., & Kusunoki, S. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.77 · Cited by 25
Stratification of responders towards eculizumab using a structural epitope mapping strategy
Volk, A.-L., Hu, F. J., Berglund, M. M., Nordling, E., Strömberg, P., Uhlén, M., & Rockberg, J. (2016) · Scientific Reports · doi:10.1038/srep31365 · Cited by 21
“The monoclonal antibody eculizumab (Soliris ® ) is the first FDA-approved therapeutic antibody for treatment of PNH 2,4,5,9 and aHUS 7,10 . humanized Eculizumab is a monoclonal antibody targeting C5.”
InfluentialEculizumab and aHUS: to stop or not
Brodsky, R. A. (2021) · Blood · doi:10.1182/blood.2020010234 · Cited by 21
Halting targeted and collateral damage to red blood cells by the complement system
Jalink, M., de Boer, E. C. W., Evers, D., Havinga, M. Q., Vos, J. M. I., Zeerleder, S. S., de Haas, M., & Jongerius, I. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00859-8 · Cited by 22
Jeda, A. S., Abbassi, S., Mousavizadeh, A., Esghaie, M., Bokharaei‐Salim, F., Jeddi, F., Shafaati, M., & Abdoli, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108232 · Cited by 26
The Complement Cascade in Kidney Disease: From Sideline to Center Stage
McCaughan, J. A., O’Rourke, D. M., & Courtney, A. E. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.12.033 · Cited by 22
Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria
Schrezenmeier, H., & Höchsmann, B. (2009) · Expert Review of Hematology · doi:10.1586/17474086.2.1.7 · Cited by 20
The role of complement in normal pregnancy and preeclampsia
Burwick, R. M., Java, A., & Regal, J. F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643896 · Cited by 25
Versmold, K., Alashkar, F., Raiser, C., Ofori‐Asenso, R., Xu, T., Liu, Y., Katz, P., Shang, A., & Röth, A. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13970 · Cited by 22
“Eculizumab is a monoclonal antibody that targets complement C5, inhibiting terminal complement activation.(4) Eculizumab was found to control intravascular hemolysis, resulting in stabilization of hemoglobin levels, reduction in the need for red blood cell transfusion, lessening of disease symptoms, and improving pati…”
BackgroundProspects for potential therapy targeting immune‑associated factors in endometriosis (Review)
Zhang, W., Li, K., Jian, A., Zhang, G., & Zhang, X. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13422 · Cited by 31
Plasma exchange for paediatric kidney disease—indications and outcomes: a single-centre experience
Reddy, S. K., Jahan, A., Chaturvedi, S., & Agarwal, I. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv084 · Cited by 19
Targeting complement cascade: an alternative strategy for COVID-19
Pandian, S. R. K., Arunachalam, S., Deepak, V., Kunjiappan, S., & Sundar, K. (2020) · 3 Biotech · doi:10.1007/s13205-020-02464-2 · Cited by 20
Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices
Muldur, S. K., Vadysirisack, D. D., Ragunathan, S., Tang, Y., Ricardo, A., Sayegh, C. E., & Irimia, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.777932 · Cited by 16
“For example, C5-inhibitor ECU, which has clinical efficacy in diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder (17), is also increasing the risk for meningococcal infections (43).”
BackgroundRisitano, A. M., de Latour, R. P., Marano, L., & Frieri, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101618 · Cited by 25
Molecular pharmacology in complement‐mediated hemolytic disorders
Bortolotti, M., Barcellini, W., & Fattizzo, B. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14026 · Cited by 21
Complement therapeutics are coming of age in rheumatology
Holers, V. M. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00981-x · Cited by 19
Fibach, E., & Dana, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.027 · Cited by 18
Anti-Complement Therapy for Glomerular Diseases
Bomback, A. S. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.12.001 · Cited by 18
Hidalgo, M. S., Merinero, H. M., López, A., Anter, J., Pinto, S., González-Fernández, F., Forés, R., López‐Trascasa, M., Villegas, A., Ojeda, E., et al. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.09.002 · Cited by 18
Ryan, M., Donato, B. M. K., Irish, W. D., Gasteyger, C., L’Italien, G., & Laurence, J. C. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00862-w · Cited by 18
Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group
Contreras, E., de la Rubia, J., del Río-Garma, J., Díaz‐Ricart, M., Gala, J. M. G., & Lozano, M. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.11.007 · Cited by 18
Subías, M., Tortajada, A., Gastoldi, S., Galbusera, M., López‐Perrote, A., Lopez, L. J., González-Fernández, F., Villegas-Martínez, A., Domínguez, M., Llorca, Ó., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402013 · Cited by 18
Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE
Hu, X., Holers, V. M., Thurman, J. M., Schoeb, T. R., Ramos, T. N., & Barnum, S. R. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.12.018 · Cited by 18
Cui, X., Chang, L., Li, Y., Lv, Q., Wang, F., Lin, Y., Li, W., Meade, J. D., Walden, J. C., & Liang, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-25652-w · Cited by 21
Myasthenia gravis: State of the art and new therapeutic strategies
Souto, E. B., Lima, B. J. D. A., Campos, J. R. S., Martins‐Gomes, C., Souto, S. B., & Silva, A. M. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577080 · Cited by 18
Zhu, W., Zhang, Y., Wang, Z., Fu, Y., & Yan, Y. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00525-3 · Cited by 17
Caruso, A., Vollmer, J., Macháček, M., & Körtvely, E. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008139 · Cited by 18
Wildes, D. M., Harvey, S., Costigan, C., Sweeney, C., Twomey, E., Awan, A., & Gorman, K. M. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-06102-w · Cited by 17
“Eculizumab is a humanized monoclonal antibody (IgG2/ IgG4) which inhibits the conversion of C5 to C5a/C5b by binding to C5 [7].”
BackgroundRisitano, A. M. (2014) · PubMed Central · doi:10.14273/unisa-231 · Cited by 18
“1-mAb) is a humanized monoclonal antibody (mAb) [43] derived from the murine anti-human C5 mAb; it binds to the complement”
BackgroundTherapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases
Pilch, K. S., Spaeth, P. J., Yuki, N., & Wakerley, B. R. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1282821 · Cited by 17
“quently did not activate complement [61].”
Kerr, H., Herbert, A. P., Makou, E., Abramczyk, D., Malik, T. H., Lomax-Browne, H. J., Yang, Y., Pappworth, I. Y., Denton, H., Richards, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681098 · Cited by 16
“Eculizumab, a mAb to complement protein C5 (13) is approved for treating PNH (14) and aHUS (15), but showed less promise in AMD (16) and C3G (17).”
BackgroundPokrass, M. J., Liu, M. F., Lindorfer, M. A., & Taylor, R. P. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.05.242 · Cited by 20
Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria
Taniguchi, K., Okada, M., Yoshihara, S., Sawada, A., Tokugawa, T., Ishii, S., Kaida, K., Ikegame, K., Minagawa, K., Matsui, T., et al. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0931-7 · Cited by 17
“In a one-compartmental model, the halflife of eculizumab after intravenous infusion was 272 h [13].”
Marotta, S., Pagliuca, S., & Risitano, A. M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.967678 · Cited by 19
“Indeed, in the recent years, the complement inhibitor eculizumab [103] became available for the treatment of complement-mediated anemia.”
BackgroundDu, Y., & Han, B. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.11.004 · Cited by 16
Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product
Gusarova, V. D., Degterev, M. B., Lyagoskin, I. V., Simonov, V., Smolov, M., Taran, S., & Shukurov, R. R. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115004 · Cited by 19
Miwa, T., Sato, S., Golla, M., & Song, W. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102405 · Cited by 18
Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review
de Zwart, P. L., Mueller, T., Spartà, G., & Luyckx, V. A. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-06216-1 · Cited by 16
Dinh, A. R., Anathasayanan, A., & Rubin, L. M. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140134 · Cited by 16
The alternative pathway of complement and the thrombotic microangiopathies
Teoh, C. W., Riedl, M., & Licht, C. P. B. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.04.012 · Cited by 21
“initiates the formation of the terminal complement complex, C5b-9) [63].”
BackgroundHarth, S., ten Haaf, A., Loew, C., Frisch, C., & Knappik, A. (2018) · mAbs · doi:10.1080/19420862.2018.1538723 · Cited by 17
Lin, K. C., Zhang, L., Kong, M., Yang, M., Chen, Y., Poptic, E. J., Hoffner, M., Xu, J. J., Tam, C. K. P., & Lin, F. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001690 · Cited by 18
Zelek, W. M., Menzies, G. E., Brancale, A., Stockinger, B., & Morgan, B. P. (2020) · Immunology · doi:10.1111/imm.13228 · Cited by 18
Passot, C., Sberro‐Soussan, R., Bertrand, D., Caillard, S., Schvartz, B., Domenger, C., Contin‐Bordes, C., Paintaud, G., Halimi, J., Ternant, D., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14627 · Cited by 16
From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage
Mastellos, D. C., Reis, E. S., Yancopoulou, D., Hajishengallis, G., Ricklin, D., & Lambris, J. D. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.06.013 · Cited by 18
“, eculizumab) has significantly improved the treatment landscape of PNH (Rother et al., 2007).”
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis
Salazar, A., Mokhtari, S., Peguero, E. N., & Jaffer, M. (2025) · Cells · doi:10.3390/cells14100739 · Cited by 22
“Eculizumab acts on C5, preventing its cleavage into C5a and C5b [55] and inhibiting the activity of the membrane attack complex while preserving proximal complement products important for chemotaxis [56].”
Carrillo-Infante, C., & Mujeebuddin, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332073 · Cited by 15
“…has been the inhibition of the terminal effector of the complement pathway, complement component 5 (C5), which prevents the formation of the terminal complement complex while preserving critical functions of upstream components that mediate pathogen opsonization and immune complex clearance [5–7].”
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.